BGB-900-105
18 Nov 2020
Trial Summary
BGB-A1217 is a humanized, IgG1 monoclonal antibody against TIGIT. Tislelizumab is a humanized, IgG4-variant monoclonal antibody against PD-1. This study tests the safety and anti-tumor effect of BGB-A1217 in combination with tislelizumab in patients with advanced solid tumors.
Acronym:
BGB-900-105
ACTRN/NCT /ethics:
NCT04047862
Scientific title:
Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors
Sponsor / Cooperative group:
BeiGene
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2019-08-26 |
| Anticipated End Date | 2024-05-01 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Nimit Singhal |
| Recruitment Status | Recruiting |
| Hospital | Southern Oncology Clinical Research Unit |
|---|---|
| Clinical Trial Coordinator | Meggan O'Riley |
| Meggan.ORiley@socru.org.au | |
| Phone | 0491 679 039 |
| Principal Investigator | Dr Amitesh Roy |
| Recruitment Status | Recruiting |